NDA 021395 · Boehringer Ingelheim
Spiriva
Tiotropium Bromide · Inhalation
NovelLast checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jan 30, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
347
124 Phase 3, 2 recruiting
FAERS reports
136,778
68,481 serious, 9,823 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2025.
SPIRIVA HANDIHALER (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HANDIHALER is indicated to reduce exacerbations in COPD patients. SPIRIVA HANDIHALER is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1 )
Mechanism: Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2009 Supplement 29 · Efficacy ReviewLabelLetter
- Jan 30, 2004 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- SPIRIVA · TIOTROPIUM BROMIDE EQ 0.018MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tiotropium" as an intervention, any sponsor and status, largest first.
- Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01126437 · 17,183 participants · Start May 2010 · Primary completion May 2013
Drug: tiotropium 18 mcg; tiotropium 1.25 mcg (2 actuations/day) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 1,191 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02296138 · 7,903 participants · Start Jan 13, 2015 · Primary completion Mar 8, 2017
Drug: olodaterol; tiotropium and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Birmingham, Alabama; Florence, Alabama · 818 sites in all
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00144339 · 5,993 participants · Start Dec 2002 · Primary completion Feb 2008
Drug: tiotropium; placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Anniston, Alabama; Birmingham, Alabama; Jasper, Alabama · 490 sites in all
- Tiotropium / Respimat One Year Study in COPD.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00387088 · 3,991 participants · Start Sep 2006 · Primary completion Jan 2009
Drug: Tiotropium · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Mobile, Alabama; Berkeley, California · 334 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
- Exacerbation StudyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00845728 · 3,439 participants · Start Mar 2009 · Primary completion Jul 2012
Drug: Indacaterol 150 µg; Tiotropium · For: Chronic Obstructive Pulmonary Disease
Sites: Buenos Aires, Argentina; Capital Federal, Argentina; Mar del Plata, Argentina · 423 sites in all
- Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01431274 · 2,624 participants · Start Sep 2011 · Primary completion Sep 2013
Drug: tiotropium + olodaterol; tiotropium and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Jasper, Alabama; Mobile, Alabama; Boulder, Colorado · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect route of drug administration23,320
- dyspnoea22,675
- asthma11,105
- drug ineffective9,516
- cough8,787
- pneumonia8,561
- wheezing6,931
- chronic obstructive pulmonary disease6,316
- product quality issue5,982
- fatigue5,465
- off label use4,786
- malaise4,629
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,291 |
| 2005 | 2,059 |
| 2006 | 1,844 |
| 2007 | 2,925 |
| 2008 | 5,102 |
| 2009 | 5,565 |
| 2010 | 6,479 |
| 2011 | 6,242 |
| 2012 | 7,661 |
| 2013 | 9,766 |
| 2014 | 10,467 |
| 2015 | 12,811 |
| 2016 | 12,445 |
| 2017 | 8,460 |
| 2018 | 7,430 |
| 2019 | 7,135 |
| 2020 | 6,729 |
| 2021 | 6,632 |
| 2022 | 4,487 |
| 2023 | 3,547 |
| 2024 | 3,258 |
| 2025 | 2,707 |
| 2026 | 1,736 |
Recalls
5 FDA enforcement reports for this application.
Jan 26, 2022 · Class II · Terminated
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Dec 14, 2017 · Class II · Terminated
Failed Stability Specifications
Mar 27, 2014 · Class III · Terminated
Defective Delivery System: Potential for dose delivery out of specification due to interation of the drug product powder with the lubricant on the interior of the capsule shell.
Aug 30, 2013 · Class III · Terminated
Presence of Foreign Substance: This recall is being conducted due to the potential for extrinsic foreign particles in the API used to manufacture SPIRIVA Handihaler
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y, Zhong NS, Li X, et al. · N Engl J Med 2017 · Clinical Trial, Phase IV, Multicenter Study
- Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
Lee HW, Park J, Jang EJ, et al. · Respir Res 2020 · Comparative Study, Systematic Review
- Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR, Hurst JR, Frent SM, et al. · Am J Respir Crit Care Med 2018 · Multicenter Study, Randomized Controlled Trial
- Combined long-acting bronchodilator single therapy for COPD.
Râjnoveanu RM, Antoniu S, Ulmeanu R · Expert Opin Pharmacother 2014 · Clinical Trial, Phase III, Multicenter Study
- The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Karner C, Cates CJ · Cochrane Database Syst Rev 2011 · Systematic Review
- Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.
Barr RG, Bourbeau J, Camargo CA, et al. · Thorax 2006 · Meta-Analysis, Research Support, N.I.H., Extramural
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.